Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christelle Lteif

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
BMC Pharmacology & Toxicology|May 9, 2019
Evaluation of prophylactic dosages of Enoxaparin in non-surgical elderly patients with renal impairmentNibal Chamoun, Hady Ghanem, Ahmad Hachem, et al.
Frontiers in Cardiovascular Medicine|March 10, 2025
Genetic variation in RYR1 is associated with heart failure progression and mortality in a diverse patient populationLeonardo A Guerra, Christelle Lteif, Yimei Huang, et al.
The Pharmacogenomics Journal|October 13, 2021
Genetic polymorphisms in ADRB2 and ADRB1 are associated with differential survival in heart failure patients taking β-blockersLeonardo A Guerra, Christelle Lteif, Meghan J Arwood, et al.
Clinical and Translational Science|April 25, 2025
Development of an Ancestrally Inclusive Preemptive Pharmacogenetic Testing PanelChristelle Lteif, Brian E Gawronski, Emily J Cicali, et al.
Frontiers in Pharmacology|May 27, 2026
CYP2D6 phenotype and post-surgical pain control with hydrocodone and oxycodoneChristelle Lteif, Rachel A Myers, Erica N Elwood, et al.
Clinical and Translational Science|February 23, 2026
Trial of Preemptive Pharmacogenetic Testing in Underserved Patients (TOPP UP): Study Framework and Baseline Characteristics of Randomized Controlled Trial ParticipantsAngel M Miranda, Christelle Lteif, Irina Fofanova, et al.
Frontiers in Pharmacology|May 13, 2025
Genetic polymorphisms in <i>SLC5A2</i> are associated with clinical outcomes and dapagliflozin response in heart failure patientsAhmed Essam Abou Warda, Rylie M Flohr, Rania M Sarhan, et al.
Clinical Pharmacology and Therapeutics|June 12, 2023
An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare ProvidersAkinyemi Oni-Orisan, Sony Tuteja, Glenda Hoffecker, et al.
Clinical Pharmacology and Therapeutics|September 20, 2025
Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine TherapyMichael T Eadon, David W Hein, Michael A Andersen, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
BMC Pharmacology & Toxicology|May 9, 2019
Evaluation of prophylactic dosages of Enoxaparin in non-surgical elderly patients with renal impairmentNibal Chamoun, Hady Ghanem, Ahmad Hachem, et al.
Frontiers in Cardiovascular Medicine|March 10, 2025
Genetic variation in RYR1 is associated with heart failure progression and mortality in a diverse patient populationLeonardo A Guerra, Christelle Lteif, Yimei Huang, et al.
The Pharmacogenomics Journal|October 13, 2021
Genetic polymorphisms in ADRB2 and ADRB1 are associated with differential survival in heart failure patients taking β-blockersLeonardo A Guerra, Christelle Lteif, Meghan J Arwood, et al.
Clinical and Translational Science|April 25, 2025
Development of an Ancestrally Inclusive Preemptive Pharmacogenetic Testing PanelChristelle Lteif, Brian E Gawronski, Emily J Cicali, et al.
Frontiers in Pharmacology|May 27, 2026
CYP2D6 phenotype and post-surgical pain control with hydrocodone and oxycodoneChristelle Lteif, Rachel A Myers, Erica N Elwood, et al.
Clinical and Translational Science|February 23, 2026
Trial of Preemptive Pharmacogenetic Testing in Underserved Patients (TOPP UP): Study Framework and Baseline Characteristics of Randomized Controlled Trial ParticipantsAngel M Miranda, Christelle Lteif, Irina Fofanova, et al.
Frontiers in Pharmacology|May 13, 2025
Genetic polymorphisms in <i>SLC5A2</i> are associated with clinical outcomes and dapagliflozin response in heart failure patientsAhmed Essam Abou Warda, Rylie M Flohr, Rania M Sarhan, et al.
Clinical Pharmacology and Therapeutics|June 12, 2023
An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare ProvidersAkinyemi Oni-Orisan, Sony Tuteja, Glenda Hoffecker, et al.
Clinical Pharmacology and Therapeutics|September 20, 2025
Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine TherapyMichael T Eadon, David W Hein, Michael A Andersen, et al.
Pageof 2